35808-68-5

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine serves as a key intermediate in the synthesis of various pharmaceuticals. Its presence in the molecular structure of target compounds contributes to their therapeutic potential, making it an essential component in drug development processes.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine is utilized as a building block for the design and synthesis of new therapeutic agents. Its structural attributes allow for the creation of molecules with specific biological activities, addressing a range of medical conditions.
Used in Drug Discovery:
4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine plays a crucial role in drug discovery, where it is employed to explore and develop novel chemical entities with potential medicinal applications. Its versatility in chemical reactions facilitates the generation of diverse molecular frameworks that can be optimized for improved pharmacological properties.
Used in Organic Chemistry:
Beyond its pharmaceutical applications, 4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine is also utilized in organic chemistry for the synthesis of other organic compounds. Its reactivity and functional group compatibility make it a valuable precursor in various organic synthesis pathways.

InChI:InChI=1/C7H6ClN3/c1-4-2-5-6(8)9-3-10-7(5)11-4/h2-3H,1H3,(H,9,10,11)

Upstream product

• 252723-16-3 4-chloro-6-methyl-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1229936-44-0 4-chloro-5-iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine 
• 35808-69-6 4-chloro-6,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine 
• 1229936-89-3 (2R,3S,5R)-5-(4-amino-6-methyl-5-(2-(2-methyl-5-phenylthiophen-3-yl)cyclopent-1-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol 
• 1219727-45-3 N-isopropyl-3-(3-(4-(6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)ureido)benzamide 
• 1414357-44-0 (S)-tert-butyl 2-((4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)pyrrolidine-1-carboxylate 
• 1613479-17-6 C₁₃H₉F₂N₃O 

Relevant academic research and scientific papers

ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY

The invention provides a series of conformationally stable and selective kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly inter

The role of alkyl substituents in deazaadenine-based diarylethene photoswitches

Diarylethenes are an important class of reversible photoswitches and often claimed to require two alkyl substituents at the carbon atoms between which the bond is formed or broken in the electrocyclic rearrangement. Here we probe this claim by the synthesis and characterization of four pairs of deazaadenine-based diarylethene photoswitches with either one or two methyl groups at these positions. Depending on the substitution pattern, diarylethenes with one alkyl group can exhibit significant photochromism, but they generally show poor stability towards extended UV irradiation, low thermal stability, and decreased fatigue resistance. The results obtained provide an important direction for the design of new efficient DNA photoswitches for the application in bionanotechnology and synthetic biology.

TREATMENT OF DRY EYE

The present disclosure provides a method of treating dry eye by inhibition of Bruton's tyrosine kinase (hereinafter "BTK") inhibitors, pharmaceutical formulations comprising the same, and processes for preparing such compounds.

Tyrosine kinase inhibitors

The present disclosure provides compounds such as pyrazolpyrimidine compounds, and pharmaceutically acceptable salts thereof, that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

The present invention relates to 6-amino-7-deaza-purine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present

REVERSIBLE COVALENT PYRROLO- OR PYRAZOLOPYRIMIDINES USEFUL FOR THE TREATMENT CANCER AND AUTOIMMUNE DISEASES

Oral pharmaceutical formulations comprising reversible covalent compounds having a Michael acceptor moiety, a process of their production, and use of these formulations for the treatment of diseases treatable by such compounds such as cancer and autoimmune diseases.

PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS

The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.

TYROSINE KINASE INHIBITORS

The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

Heterocyclic Compounds Useful as RAF Kinase Inhibitors

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.